AQR Capital Management LLC Has $37,000 Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

AQR Capital Management LLC boosted its holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 70.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,333 shares of the biopharmaceutical company’s stock after purchasing an additional 12,934 shares during the quarter. AQR Capital Management LLC owned 0.06% of Marinus Pharmaceuticals worth $37,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the second quarter valued at about $727,000. Wellington Management Group LLP lifted its holdings in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after acquiring an additional 85,455 shares during the period. Vanguard Group Inc. boosted its position in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares in the last quarter. Acadian Asset Management LLC bought a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $813,000. Finally, Hussman Strategic Advisors Inc. raised its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares in the last quarter. Institutional investors own 98.80% of the company’s stock.

Analysts Set New Price Targets

MRNS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research note on Monday, September 23rd. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. StockNews.com upgraded Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $1.85 on Friday. The firm has a fifty day moving average of $1.54 and a 200 day moving average of $1.81. Marinus Pharmaceuticals, Inc. has a 52-week low of $1.05 and a 52-week high of $11.26. The firm has a market capitalization of $101.63 million, a PE ratio of -0.70 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. During the same period in the prior year, the firm earned ($0.61) earnings per share. On average, sell-side analysts forecast that Marinus Pharmaceuticals, Inc. will post -1.93 EPS for the current fiscal year.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.